Over the past 12 months, 5 insiders at RECURSION PHARMACEUTICALS, INC. filed 38 open-market SEC Form 4 transactions on RXRX: 0 purchases worth $0 and 38 sales worth $13.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 7, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 26 | Blake Borgeson | SELL | 40.0K | $3.96 | $159K |
| Jun 18, 26 | Namandje Bumpus | SELL | 4.0K | $3.18 | $13K |
| Jun 5, 26 | Christopher Gibson | SELL | 40.0K | $3.62 | $145K |
| Jun 3, 26 | Namandje Bumpus | SELL | 4.4K | $3.54 | $16K |
| Jun 2, 26 | Blake Borgeson | SELL | 30.0K | $3.68 | $110K |
| May 22, 26 | Christopher Gibson | SELL | 40.0K | $3.08 | $123K |
| May 7, 26 | Christopher Gibson | SELL | 40.0K | $3.37 | $135K |
| May 5, 26 | Blake Borgeson | SELL | 30.0K | $3.52 | $106K |
| Apr 22, 26 | Christopher Gibson | SELL | 40.0K | $3.61 | $144K |
| Apr 7, 26 | Blake Borgeson | SELL | 30.0K | $3.10 | $93K |
| Apr 7, 26 | Christopher Gibson | SELL | 40.0K | $3.10 | $124K |
| Mar 23, 26 | Christopher GibsonDirector | SELL | 40.0K | $3.25 | $130K |
| Mar 17, 26 | Ben R TaylorChief Financial Officer | SELL | 8.0K | $3.39 | $27K |
| Mar 9, 26 | Najat KhanCEO and President | SELL | 28.3K | $3.35 | $95K |
| Mar 3, 26 | Blake BorgesonDirector | SELL | 170.0K | $3.46 | $588K |
| Feb 19, 26 | Christopher GibsonDirector | SELL | 40.0K | $3.46 | $138K |
| Feb 18, 26 | Ben R TaylorChief Financial Officer | SELL | 13.4K | $3.08 | $41K |
| Feb 4, 26 | Christopher GibsonDirector | SELL | 40.0K | $4.12 | $165K |
| Feb 3, 26 | Blake BorgesonDirector | SELL | 220.0K | $4.20 | $924K |
| Jan 20, 26 | Christopher GibsonDirector | SELL | 40.0K | $4.47 | $179K |
| Jan 6, 26 | Blake BorgesonDirector | SELL | 220.0K | $4.36 | $959K |
| Jan 5, 26 | Christopher GibsonDirector | SELL | 40.0K | $4.25 | $170K |
| Dec 29, 25 | Ben R TaylorChief Financial Officer | SELL | 21.4K | $4.18 | $89K |
| Dec 22, 25 | Najat KhanChief R&D Commercial Officer | SELL | 124.4K | $4.41 | $549K |
| Dec 19, 25 | Christopher GibsonChief Executive Officer | SELL | 40.0K | $4.50 | $180K |
| Dec 4, 25 | Christopher GibsonChief Executive Officer | SELL | 40.0K | $4.63 | $185K |
| Dec 2, 25 | Blake BorgesonDirector | SELL | 220.0K | $4.37 | $961K |
| Nov 19, 25 | Christopher GibsonChief Executive Officer | SELL | 40.0K | $4.16 | $166K |
| Nov 4, 25 | Christopher GibsonChief Executive Officer | SELL | 40.0K | $5.21 | $208K |
| Oct 23, 25 | Christopher GibsonChief Executive Officer | SELL | 100.0K | $5.70 | $570K |
| Oct 10, 25 | Christopher GibsonChief Executive Officer | SELL | 100.0K | $6.04 | $604K |
| Sep 25, 25 | Christopher GibsonChief Executive Officer | SELL | 100.0K | $4.76 | $476K |
| Sep 10, 25 | Christopher GibsonChief Executive Officer | SELL | 100.0K | $4.71 | $471K |
| Aug 26, 25 | Christopher GibsonChief Executive Officer | SELL | 100.0K | $4.84 | $484K |
| Aug 18, 25 | Najat KhanChief R&D Commercial Officer | SELL | 36.6K | $5.52 | $202K |
| Aug 11, 25 | Christopher GibsonChief Executive Officer | SELL | 500.3K | $5.28 | $2.6M |
| Mar 27, 25 | Christopher GibsonChief Executive Officer | SELL | 138.6K | $6.04 | $837K |
| Mar 6, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $6.37 | $127K |
| Mar 5, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $6.58 | $132K |
| Feb 6, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $8.12 | $162K |
| Feb 5, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.68 | $154K |
| Jan 10, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.05 | $141K |
| Jan 8, 25 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.31 | $146K |
| Dec 5, 24 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.12 | $142K |
| Dec 4, 24 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.16 | $143K |
| Nov 14, 24 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.35 | $147K |
| Nov 13, 24 | Christopher GibsonChief Executive Officer | SELL | 20.0K | $7.74 | $155K |
| Nov 13, 24 | Michael SecoraChief Financial Officer | SELL | 15.0K | $7.66 | $115K |
| Nov 12, 24 | Blake BorgesonDirector | SELL | 11.4K | $7.64 | $87K |
| Nov 12, 24 | Michael SecoraChief Financial Officer | SELL | 15.0K | $7.64 | $115K |
Over the past 12 months, insiders at RECURSION PHARMACEUTICALS, INC. filed 0 open-market purchases worth $0 and 38 sales worth $13.0M on RXRX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 7, 26.
5 different insiders at RECURSION PHARMACEUTICALS, INC. filed open-market SEC Form 4 transactions on RXRX over the last 12 months.
InsiderTape plots every RXRX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every RECURSION PHARMACEUTICALS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →